IMMUNOLOGY2026™ Conference Recordings For Attendees-A universal CD4 epitope enhances cytotoxic T-cell priming and memory in glioblastoma peptide vaccination

A universal CD4 epitope enhances cytotoxic T-cell priming and memory in glioblastoma peptide vaccination

Video Transcription

Video Summary

Kelly Hotchkiss described a Duke phase 1 glioblastoma vaccine trial designed to overcome tumor heterogeneity and immune suppression. The team combined a tetanus-derived recall antigen (P30) with tumor-associated antigens to boost both CD4 and CD8 responses, using a priming-and-boosting schedule with adjuvant support. In 18 patients, the vaccine was safe, generated immune responses, and some patients achieved prolonged survival, with seven alive at one year. Immune profiling showed T-cell expansion and increased CD8 infiltration into tumors. The group is now developing a personalized neoantigen version of the vaccine.

Meta Tag

Date April 18, 2026 1:30 PM - 1:45 PM

Room 205

Session Molecular Mechanisms of Tumor Immunity

Speaker Kelly Hotchkiss

Track Tumor Immunology: Checkpoints, Prevention, And Treatment (TIPT)

Year 2026

Keywords

glioblastoma vaccine

tumor heterogeneity

tetanus-derived antigen

CD4 CD8 immune response

personalized neoantigen

April 18, 2026 1:30 PM - 1:45 PM

205

Molecular Mechanisms of Tumor Immunity

Kelly Hotchkiss

Tumor Immunology: Checkpoints, Prevention, And Treatment (TIPT)

2026